Physician profile
David A Abbott
NPI 1568448850
$6,173.44
in general payments reported to CMS, 2019-2025
35 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $982 · 2021: $1,357 · 2022: $850 · 2023: $1,076 · 2024: $545 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784 · Education: $80.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.91 |
| Education | $80.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $698.14 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $606.67 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $510.75 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $503.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $363.92 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $333.70 | 2021-2023 | Qulipta |
| Biogen, INC. | $228.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.48 | 2021-2025 | |
| Amgen INC. | $189.51 | 2021-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $160.72 | 2021 | |
| Pfizer INC. | $160.50 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $129.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $126.69 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $118.17 | 2019-2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.